INTRODUCTION: Translocations of the anaplastic lymphoma kinase (ALK) can be effectively targeted in advanced non-small cell lung cancer by ALK-TKI inhibitors including Crizotinib. However. the development of acquired resistance often limits the duration of these therapies. While several mechanisms of secondary resistance have been already identified. https://echobasetoysmyshopifyes.shop/product-category/die-cast/